
## Elisabetta Maffioletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9105316/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders. European Neuropsychopharmacology, 2022, 54, 41-53.	0.7	4
2	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. European Neuropsychopharmacology, 2022, 55, 112-157.	0.7	7
3	Biological correlates of early life stressful events in major depressive disorder. Psychoneuroendocrinology, 2021, 125, 105103.	2.7	23
4	Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future. Brain Sciences, 2021, 11, 1120.	2.3	11
5	Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients. Högre Utbildning, 2021, 12, 1987655.	3.0	16
6	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA) Tj ETQq0 0 0	rgB <b>I.6</b> Ovei	flocte 10 Tf 50
7	P.264 Association of single nucleotide polymorphisms in the 3' untranslated region of SLC1A2 with major depressive disorder and relative endophenotypes. European Neuropsychopharmacology, 2020, 40, S150-S151.	0.7	0
8	Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. Genes, 2020, 11, 1089.	2.4	17
9	Association study between <scp><i>HTR2A</i></scp> rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug Development Research, 2020, 81, 754-761.	2.9	15
10	Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response. Drug Development Research, 2020, 81, 593-599.	2.9	14
11	miR-146a Plasma Levels Are Not Altered in Alzheimer's Disease but Correlate With Age and Illness Severity. Frontiers in Aging Neuroscience, 2020, 11, 366.	3.4	17
12	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2019, 82, 102-109.	3.1	76
13	F49GENETIC DETERMINANTS OF CIRCULATING VEGF LEVELS IN MAJOR DEPRESSIVE DISORDER. European Neuropsychopharmacology, 2019, 29, S1135-S1136.	0.7	0
14	BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. Journal of ECT, 2019, 35, 189-194.	0.6	19
15	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2307-2312.	2.2	7
16	Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes. Molecular and Cellular Neurosciences, 2017, 85, 220-225.	2.2	11
17	Peripheral whole blood microRNA alterations in major depression and bipolar disorder. Journal of Affective Disorders, 2016, 200, 250-258.	4.1	138
18	Nanomedicine in Psychiatry: New Therapeutic Opportunities from Research on Small RNAs. Drug Development Research, 2016, 77, 453-457.	2.9	4

#	Article	IF	CITATIONS
19	Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. Journal of Molecular Neuroscience, 2015, 56, 681-687.	2.3	35
20	Effetti biomolecolari del maltrattamento infantile: il ruolo dell'epigenetica e dell'infiammazione. Maltrattamento E Abuso All'Infanzia, 2015, , 35-54.	0.5	3
21	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. Acta Psychiatrica Scandinavica, 2014, 129, 461-466.	4.5	34
22	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Frontiers in Cellular Neuroscience, 2014, 8, 75.	3.7	100
23	Defining an immune signature predictive of glioma progression. Journal of Neuroimmunology, 2014, 275, 35.	2.3	0
24	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. BioTechniques, 2014, 57, 111-114.	1.8	34
25	Blood microRNA changes in depressed patients during antidepressant treatment. European Neuropsychopharmacology, 2013, 23, 602-611.	0.7	197
26	ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS. Depression and Anxiety, 2013, 30, 1170-1176.	4.1	42